AMGN

Amgen Inc

AMGN, USA

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

https://www.amgen.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

2.52

Next Payout:

Mar 6, 2026

Yield:

3.1190 %
AMGN
stock
AMGN

Notable Wednesday Option Activity: CRUS, AMGN, HUM Nasdaq

Read more →
AMGN
stock
AMGN

XLV, AMGN, GILD, DHR: ETF Inflow Alert Nasdaq

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$331.5926

Analyst Picks

Strong Buy

10

Buy

5

Hold

14

Sell

1

Strong Sell

2

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

25.57

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

18.21

Low 1

High 3

Return on Equity (ROE)

-

Very High

33.43 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

3.57 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

44.45 %

Low 5%

High 15%

Debt to Equity

-

Very Low

8.37

Low 1

High 0.3

Investors

* Institutions hold a combined 77.41% of the total shares of Amgen Inc

1.

Vanguard Group Inc

(9.9769%)

since

2025/06/30

2.

BlackRock Inc

(8.6556%)

since

2025/06/30

3.

State Street Corp

(5.453%)

since

2025/06/30

4.

Capital Research & Mgmt Co - Division 3

(3.5127%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.1391%)

since

2025/07/31

6.

Capital World Investors

(3.1316%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(3.0063%)

since

2025/06/30

8.

Vanguard 500 Index Investor

(2.4723%)

since

2025/07/31

9.

Geode Capital Management, LLC

(2.4182%)

since

2025/06/30

10.

Charles Schwab Investment Management Inc

(2.395%)

since

2025/06/30

11.

Invesco QQQ Trust

(2.0586%)

since

2025/08/29

12.

PRIMECAP Management Company

(1.9748%)

since

2025/06/30

13.

Schwab US Dividend Equity ETF™

(1.7606%)

since

2025/08/30

14.

Capital Group Wash Mutual Invtrs Comp

(1.6582%)

since

2025/06/30

15.

American Funds Washington Mutual A

(1.6582%)

since

2025/06/30

16.

Wells Fargo & Co

(1.358%)

since

2025/06/30

17.

Fidelity 500 Index

(1.2661%)

since

2025/07/31

18.

Vanguard PRIMECAP Inv

(1.2491%)

since

2025/06/30

19.

Laurel Wealth Advisors, LLC

(1.2446%)

since

2025/06/30

20.

SPDR® S&P 500® ETF

(1.207%)

since

2025/08/31

21.

iShares Core S&P 500 ETF

(1.2018%)

since

2025/08/31

22.

Northern Trust Corp

(1.1408%)

since

2025/06/30

23.

NORGES BANK

(1.1068%)

since

2025/06/30

24.

Bank of America Corp

(1.0348%)

since

2025/06/30

25.

SPDR® Dow Jones Industrial Avrg ETF Tr

(0.9906%)

since

2025/08/31

26.

UBS Asset Mgmt Americas Inc

(0.9812%)

since

2025/06/30

27.

American Funds American Mutual A

(0.9784%)

since

2025/06/30

28.

Capital Group American Mutual Comp

(0.9784%)

since

2025/06/30

29.

Vanguard Value Index Inv

(0.8852%)

since

2025/07/31

30.

American Funds American Balanced A

(0.8766%)

since

2025/06/30

31.

Capital Research Global Investors

(0.8561%)

since

2025/06/30

32.

UBS Group AG

(0.8503%)

since

2025/06/30

33.

Royal Bank of Canada

(0.8427%)

since

2025/06/30

34.

Loomis Sayles Long Corp Disc Alpha

(0.8158%)

since

2025/06/30

35.

Goldman Sachs Group Inc

(0.7859%)

since

2025/06/30

36.

Amvescap Plc.

(0.7783%)

since

2025/06/30

37.

American Funds Income Fund of Amer A

(0.7437%)

since

2025/06/30

38.

The Health Care Select Sector SPDR® ETF

(0.682%)

since

2025/08/31

39.

American Funds Capital Income Bldr A

(0.6813%)

since

2025/06/30

40.

Vanguard Institutional Index I

(0.6038%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

4.72

Latest Release

Date

2025-09-30

EPS Actual

5.64

EPS Estimate

5.02

EPS Difference

0.62

Surprise Percent

12.3506%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(9.3)
GARP
Strong GARP(6.5)
Growth
High Growth(6.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.